This study investigates the use of a personalized mRNA vaccine combined with a PD-1 inhibitor as adjuvant therapy for patients who cannot tolerate chemotherapy after pancreatic cancer surgery.
The study evaluates the safety and tolerability of this combination therapy. It also looks at how the treatment affects certain immune cells and measures outcomes like recurrence-free survival and overall survival.
- Who can participate: Adults aged 18 and older who have had surgery for pancreatic cancer and cannot tolerate chemotherapy may participate. Eligibility includes specific genetic markers and absence of recent conflicting treatments.
- Study details: Participants will receive a combination of an investigational mRNA vaccine and a PD-1 inhibitor.
How understandable was the trial content above?
Hard to understand
Easy to understand